Targeted therapy with sunitinib or sorafenib combining with gemcitabine plus cisplatin in the treatment of metastatic collecting duct carcinoma of the kidney.

Trial Profile

Targeted therapy with sunitinib or sorafenib combining with gemcitabine plus cisplatin in the treatment of metastatic collecting duct carcinoma of the kidney.

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Apr 2016

At a glance

  • Drugs Sorafenib (Primary) ; Sunitinib (Primary) ; Cisplatin; Gemcitabine
  • Indications Renal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 May 2012 Actual end date (14 Aug 2010) added as reported by Chinese Clinical Trial Register.
    • 15 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top